Stem Cell Patent Case Will Be Early Test Of Myriad's Reach

Law360, New York (July 10, 2013, 8:55 PM EDT) -- A suit seeking to invalidate a patent on human embryonic stem cells could provide some early indication as to whether the U.S. Supreme Court's ruling that isolated DNA cannot be patented applies to other technology involving natural material, attorneys say.

Filed less than three weeks after the high court's decision, Consumer Watchdog's appeal to the Federal Circuit argues that a stem cell patent held by the Wisconsin Alumni Research Foundation is a product of nature that is not eligible for a patent, like Myriad Genetics Inc.'s patents on human genes.

The case appears to be the first attempt to use the...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS